142 assets in Cutaneous Melanoma

Therapeutic assets addressing Cutaneous Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Azathioprine Cutaneous Melanoma	Therakos LLC	P2	CCC (53)
Dinaciclib Cutaneous Melanoma	National Cancer Institute (NCI)	P2	CCC (53)
Endostatin Cutaneous Melanoma	Fudan University	P2	CCC (53)
Fianlimab Cutaneous Melanoma	University of California, Irvine	P2	CCC (53)
Fluorouracilum Cutaneous Melanoma	Immuneering Corporation	P1/2	CCC (53)
Iscib1 Cutaneous Melanoma	Scancell Ltd	P2	CCC (53)
Lidocaine Cutaneous Melanoma	Ohio State University Comprehensive Cancer Center	P2	CCC (53)
Nemvaleukin Alfa Cutaneous Melanoma	Mural Oncology, Inc	P2	CCC (53)
Odetiglucan Cutaneous Melanoma	HiberCell, Inc.	P2	CCC (53)
Oncolytic Virus Rp1 Cutaneous Melanoma	Replimune, Inc.	P2	CCC (53)
Oxaliplatin Cutaneous Melanoma	Immuneering Corporation	P1/2	CCC (53)
Pucotenlimab Cutaneous Melanoma	Shanghai Zhongshan Hospital	P2	CCC (53)
Recombinant Human Hyaluronidase Cutaneous Melanoma	Emory University	P2	CCC (53)
Rigosertib Cutaneous Melanoma	Vanderbilt-Ingram Cancer Center	P2	CCC (53)
Rituximab Cutaneous Melanoma	Emory University	P2	CCC (53)
Scib1 Cutaneous Melanoma	Scancell Ltd	P2	CCC (53)
Tebentafusp Cutaneous Melanoma	University of Oxford	P2	CCC (53)
Teonanacatl Cutaneous Melanoma	Psyence Australia Pty Ltd	P2	CCC (53)
Toripalimab Cutaneous Melanoma	Fudan University	P2	CCC (53)
VITPSO Cutaneous Melanoma	Therakos LLC	P2	CCC (53)
18f-flt Cutaneous Melanoma	ECOG-ACRIN Cancer Research Group	P2	CCC (52)
Capivasertib Cutaneous Melanoma	Aminex Therapeutics, Inc.	P1/2	CCC (52)
Imm-6-415 Cutaneous Melanoma	Immuneering Corporation	P1/2	CCC (52)
Eribulin Cutaneous Melanoma	GI Innovation, Inc.	P1/2	CCC (50)
[212pb]vmt01 Cutaneous Melanoma	Perspective Therapeutics	P1/2	CCC (48)
anv419 Cutaneous Melanoma	Anaveon AG	P1/2	CCC (48)
Benzamide, 3-((3-Endo)-8-(2-((Cyclohexylmethyl)((2S)-2,3-Dihydroxy-1-Oxopropyl)Amino)Ethyl)-8-Azabicyclo(3.2.1)Oct-3-Yl)- Cutaneous Melanoma	John Kirkwood	P1/2	CCC (48)
bi-1607 Cutaneous Melanoma	BioInvent International AB	P1/2	CCC (48)
Eb-Dtkn-401 Allogeneic Dual-Target Cspg4/Gd2 Car-Nk Cells Cutaneous Melanoma	Beijing Biotech	P1/2	CCC (48)
Gamma4 Heavy Chain Homo Sapiens (1-446) [Vh (Homo Sapiens Ighv4-3901 (96.0%) -(Ighd) -Ighj302 (100%), Cdr-Imgt [10.7.12] (26-35.53-59.98-109)) (1-120)-Homo Sapiens Ighg401, Ng4M(A) Ch2 L92, G4V5 H P10, G4V4 Ch2 A1.3, A1.2 (Ch1 (121-218), Hinge 1-12 S10>P (228) (219-230), Ch2 F1.3>A (234), L1.2>A (235), L92 (309) (231-340), Ch3 (341-445), Chs K2>Del (446)) (121-446)], (134-215')-Disulfide With Kappa Light Chain Homo Sapiens (1'-215') [V-Kappa (Homo Sapiens Igkv1-3301 (96.8%) -Igkj401 (100%), Cdr-Imgt[6.3.10] (27'-32'.50'-52'.89'-98')) (1'-108') -Homo Sapiens Igkc01 (100%), Km3 A45.1 (154'), V101 (192') (109'-215')], Dimer (226-226'':229-229'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho)-K1Sv Cell Line Lacking The Glutamine Synthetase Gene (Gs-Ko), Glycoform Alfa Cutaneous Melanoma	Innovent Biologics (Suzhou) Co. Ltd.	P1/2	CCC (48)
Imm-1-104 Cutaneous Melanoma	Immuneering Corporation	P1/2	CCC (48)
Tazemetostat Hydrobromide Cutaneous Melanoma	National Cancer Institute (NCI)	P1/2	CC (47)
Amxt 1501 Dicaprate Cutaneous Melanoma	Aminex Therapeutics, Inc.	P1/2	CC (45)
Apg 115 Cutaneous Melanoma	Ascentage Pharma Group Inc.	P1/2	CC (45)
Avutometinib Cutaneous Melanoma	University of Utah	P1/2	CC (45)
Crizotinib Cutaneous Melanoma	IDEAYA Biosciences	P1/2	CC (45)
Darovasertib Cutaneous Melanoma	IDEAYA Biosciences	P1/2	CC (45)
Decitabine Cutaneous Melanoma	Roswell Park Cancer Institute	P1/2	CC (45)
Defactinib Cutaneous Melanoma	University of Utah	P1/2	CC (45)
Dual-Target Antigen-Selected Car-Nk Cutaneous Melanoma	Essen Biotech	P1/2	CC (45)
Ebnk-001 Cutaneous Melanoma	Essen Biotech	P1/2	CC (45)
Eb-Select Single-Target Car-Nk Cells Cutaneous Melanoma	Essen Biotech	P1/2	CC (45)
Eflornithine Cutaneous Melanoma	Aminex Therapeutics, Inc.	P1/2	CC (45)
Env-501 Cutaneous Melanoma	Hummingbird Bioscience	P1/2	CC (45)
Fulvestrant Cutaneous Melanoma	Aminex Therapeutics, Inc.	P1/2	CC (45)
gi-102 Cutaneous Melanoma	GI Innovation, Inc.	P1/2	CC (45)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Il2 (Interleukin 2)], Homo Sapiens Antibody; Gamma1 Heavy Chain Homo Sapiens (1-451) [Vh (Homo Sapiens Ighv1-2401 (84.5%) -(Ighd) -Ighj401 (92.9%), Cdr-Imgt [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo Sapiens Ighg101, G1M17,1, G1V43 Ch2 A1.3, E1.2, A1 (Ch1 K120 (218) (122-219), Hinge 1-15 (220- 234), Ch2 L1.3>A (238), L1.2>E (239), (235- 344), Ch3 (345-449), Chs (450-451)) (122-451)], (224-220')-Disulfide With Kappa Light Chain Homo Sapiens (1'-220') [V-Kappa (Homo Sapiens Igkv4-101 (88.1%) -Igkj401 (90.9%), Cdr-Imgt [12.3.9] (27-38.56-58.95-103)) (1'-113') -Homo Sapiens Igkc01 (100%), Km3, A45.1 (159), V101 (197) (114'- 220')]; Dimer(230-230'':233-233'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1, Glycoform Alfa Cutaneous Melanoma	Aulos Bioscience, Inc.	P1/2	CC (45)
Interleukin-15 Cutaneous Melanoma	Essen Biotech	P1/2	CC (45)
kb707 Cutaneous Melanoma	Krystal Biotech, Inc.	P1/2	CC (45)
Mdna11 Cutaneous Melanoma	Medicenna Therapeutics, Inc.	P1/2	CC (45)

Showing 51 to 100 of 142 assets

PreviousPage 2 of 3Next